Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00015977 | Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 13 | University of ChicagoOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00258284 | Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 6, 2014 | clinicaltrials |
| NCT00078923 | Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate | completed | Phase 2 | 32 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 5, 2014 | clinicaltrials |
| NCT00887640 | Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer | terminated | Phase 2 | 11 | Duke UniversityOTHER | 1 | Feb 26, 2014 | clinicaltrials |
| NCT01734681 | Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | GenSpera, Inc.INDUSTRY | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01176513 | GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer | terminated | Phase 2 | 25 | GE HealthcareINDUSTRY | 1 | Feb 14, 2014 | clinicaltrials |
| NCT01409473 | Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer(Prostate SBRT) | withdrawn | Phase 2 | 0 | Rocky Mountain Cancer CentersOTHER | 1 | Feb 12, 2014 | clinicaltrials |
| NCT01715064 | Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients | completed | Phase 2 / Phase 3 | 36 | University of Guelph-HumberOTHER | 1 | Feb 10, 2014 | clinicaltrials |
| NCT00295802 | Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer | unknown | Phase 2 / Phase 3 | 141 | EDAP TMS S.A.INDUSTRY | 2 | Feb 7, 2014 | clinicaltrials |
| NCT01250717 | Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer | completed | Phase 2 | 28 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 4, 2014 | clinicaltrials |
| NCT00003312 | Brachytherapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 95 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 24, 2014 | clinicaltrials |
| NCT00479635 | A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 26 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 22, 2014 | clinicaltrials |
| NCT02037464 | CAPSAICIN Trial: Assessing Capsaicin as a Chemopreventive Agent for Prostate Cancer(CAPSAICIN) | unknown | Phase 2 | 100 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 16, 2014 | clinicaltrials |
| NCT00922129 | Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT01000948 | A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer(DAPROCA-1) | terminated | Phase 2 | 24 | Aarhus University HospitalOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00917865 | FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer | terminated | Phase 2 | 11 | David M. Schuster, MDOTHER | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00002775 | Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 37 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003124 | Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 105 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003717 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | unknown | Phase 2 | 17 | St. Barnabas Medical CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00433797 | Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 86 | University of OsloOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00045123 | R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence | unknown | Phase 2 | — | Myrexis Inc.INDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT01491971 | Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer(IM1) | completed | Phase 2 | 76 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 12, 2013 | clinicaltrials |
| NCT00510224 | Sandostatin for Patients With Androgen Independent Prostate Cancer | terminated | Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT00684970 | Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)(TLH-202) | unknown | Phase 2 | 100 | Tiltan Pharma Ltd.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT00003183 | Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 64 | Hope Cancer Institute, Inc.INDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00005960 | Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | unknown | Phase 2 | — | AmgenINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00181597 | Trilostane for Androgen-Independent Prostate Cancer | completed | Phase 2 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 3, 2013 | clinicaltrials |
| NCT01487720 | GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer | completed | Phase 2 | 33 | Asan Medical CenterOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00681148 | Botulinum Toxin Injection With Prostate Brachytherapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT00086736 | Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy | completed | Phase 2 | 34 | University of Alabama at BirminghamOTHER | 1 | Nov 19, 2013 | clinicaltrials |
| NCT00945477 | Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade | terminated | Phase 2 | 11 | Illinois CancerCare, P.C.OTHER | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00005939 | Brachytherapy in Treating Patients With Recurrent Prostate Cancer | unknown | Phase 1 / Phase 2 | — | Center for Molecular MedicineOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00054015 | 3-AP in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | — | Vion PharmaceuticalsINDUSTRY | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00348998 | Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | unknown | Phase 2 | 18 | Virginia Mason Hospital/Medical CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00814892 | Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Nov 5, 2013 | clinicaltrials |
| NCT01481233 | Oral Colchicine in Men With Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Milton S. Hershey Medical CenterOTHER | 0 | Sep 27, 2013 | clinicaltrials |
| NCT00020995 | Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer | completed | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00354497 | Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men | unknown | Phase 2 | 800 | Lawrence Livermore National Laboratory at University of CaliforniaOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00765479 | Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer | completed | Phase 2 / Phase 3 | 284 | University of Illinois at ChicagoOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00006002 | SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 36 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00561262 | High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 60 | University College London HospitalsOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00561314 | High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 33 | University College London HospitalsOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00987675 | High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer | unknown | Phase 2 | 26 | University College London HospitalsOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00988130 | High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer | unknown | Phase 2 | 26 | University College London HospitalsOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01193855 | Dutasteride in Treating Patients With Prostate Cancer | unknown | Phase 2 | 42 | University College London HospitalsOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00908141 | GM-CSF in Treating Patients With Relapsed Prostate Cancer | completed | Phase 2 | 17 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 23, 2013 | clinicaltrials |
| NCT00685633 | Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Aug 20, 2013 | clinicaltrials |
| NCT00425334 | Safety Study of Hemospan® in Prostatectomy Patients | completed | Phase 2 | 20 | SangartINDUSTRY | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00554918 | Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy | completed | Phase 2 | 300 | University Hospital BirminghamOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT01909388 | Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy(BRAPROST) | unknown | Phase 2 | 15 | Alfonso Gomez-IturriagaOTHER | 1 | Jul 26, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Mar 7, 2014source: clinicaltrials